HI-Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HI-Bio - overview
Established
2021
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2021, Human Immunology Biosciences, Inc. trading as HI-Bio, operates as a biotechnological company developing precision medicines to treat people suffering from autoimmune and inflammatory diseases. In November 2022, HI-Bio raised USD 120 million in venture funding from Jeito Capital, with participation from ARCH Venture Partners and Monograph Capital Partners. As of December 2022, the company is led by its CEO Travis Murdoch.
Human Immunology Biosciences, Inc. develops a slate of precision medicines targeting cellular drivers of this dysfunction, including its lead program, the plasma depletion agent felzartamab. It provides a precision immunology toolkit consisting of four pillars human genetics, human immunophenotyping, data sciences, and therapeutic engineering that helps translate insights that emerge from ongoing research and development efforts. The company plans to use the venture funding to further develop precision therapeutics for patients with immune-mediated diseases.
Current Investors
ARCH Venture Partners, Jeito Capital, Monograph Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.hibio.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.